Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Nanoparticle Traps Represent a Radical New Method for Treating Viral Infections

By BiotechDaily International staff writers
Posted on 20 Jan 2014
Print article
Image: Virus-infected cells after treatment with Vecoy nanoparticles (indicated by arrows) (Photo courtesy of Vecoy Nanomedicines).
Image: Virus-infected cells after treatment with Vecoy nanoparticles (indicated by arrows) (Photo courtesy of Vecoy Nanomedicines).
An Israeli biotechnology start-up company is researching a radically different approach to the problem of preventing and curing viral infections.

Traditional drug treatment attempts to destroy viruses after they already have invaded host cells and caused significant damage by initiating the disease process (fever, nausea, diarrhea, etc.) in the infected individual. A radically new approach to cure viral infections is under development at Vecoy Nanomedicines (Kiryat Ono, Israel).

The Vecoy (a virus decoy) is an artificial nanoparticle coated with viral receptors. The virus reacts to the nanoparticle in the same way it would to a normal target cell, but once trapped inside, it is immobilized and prevented from spreading the infection. Thus, the Vecoy technology successfully addresses the two major challenges of current medication, namely, virus resistance to treatment and toxicity effects.

Results of cell-culture and preclinical studies in Vecoy’s laboratories demonstrate neutralization of 97% percent of viruses in culture with efficacy expected to rise as the technique is refined. The method is patent pending and funding is being secured to conduct animal trials.

“Viruses are one of the most polymorphic and resilient organisms out there,” said Dr. Erez Livneh, CEO of Vecoy Nanomedicines. “They are rapidly changing, and can change anything in their genome, either by changing their exterior so our immune system would not recognize them or by changing their enzymes so that the handful of drugs we have will not affect them anymore. With the current state of overpopulation of our planet and international flights, we are now prone more than ever before to new viral pandemics which will be very hard to contain, and it is just a matter of time. We had better be in a position where we can do something about it.”

Related Links:

Vecoy Nanomedicines



Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Drug Discovery

view channel
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).

First High-Throughput Imaging Platform for Predicting Kidney Toxicity of Chemicals

Researchers have developed a high-throughput platform of automated cellular imaging that efficiently and accurately predicts renal toxicity of chemical compounds without animal testing, providing an improved... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.